Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2 · ActiveModality: allogeneic CAR NK cell therapy
Target CD19
Partnerships University of California, Irvine (investigator-sponsored Phase 1 trial in myasthenia gravis); Columbia University Irving Medical Center (investigator-sponsored Phase 1 trial in SLE)
Indications
lupus nephritis (Ntrust-1)(Stage not disclosed)
primary membranous nephropathy (Ntrust-1)(Stage not disclosed)
systemic sclerosis / scleroderma (Ntrust-2)(Stage not disclosed)
idiopathic inflammatory myopathy (Ntrust-2)(Stage not disclosed)
ANCA-associated vasculitis (Ntrust-2)(Stage not disclosed)
rheumatoid arthritis (Ntrust-2)(Stage not disclosed)
myasthenia gravis (investigator-sponsored)(Stage not disclosed)
systemic lupus erythematosus (investigator-sponsored)(Stage not disclosed)
Status note Lead program. Ntrust-1 and Ntrust-2 are open-label dose-escalation Phase 1/2 trials; protocol amendments in April 2026 enable outpatient administration. Prior Phase 1 oncology study in B-cell malignancies closed enrollment in 2023; oncology deprioritized.
NKX101
Phase 1 · ActiveModality: allogeneic CAR NK cell therapy
Target NKG2D ligands
Indications
hematologic malignancies(Stage not disclosed)
Status note Oncology Phase 1 studies for NKX019 and NKX101 closed patient enrollment in 2023 and were deprioritized to direct primary resources to NKX019 in autoimmune diseases. FDA orphan drug designation for NKX101 in acute myeloid leukemia granted December 2021.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.